A Roche drug in development as a treatment for spinal muscular atrophy achieved the main goals of a key study, helping to build the case that the drug could challenge a Biogen therapy already approved for the rare disorder.
CEO and Fund Manager, Renaissance Venture Capital Fund
President & CEO, Indiana Biosciences Research Institute
Professor, Michigan State University
Vice President for Corporate Engagement, Rose-Hulman Institute of Technology
Danish diabetes giant Novo Nordisk took another step this week in its efforts to establish a presence in nonalcoholic steatohepatitis, or NASH, a metabolic disorder closely related to diabetes that is anticipated to become the leading cause of liver transplants in... Read more »
When Mark Bakken formed the healthcare technology investment firm HealthX Ventures nearly five years ago, he says hospitals, insurers, and other potential buyers of digital health products were less open to conversations with the kinds of early-stage healthtech startups Bakken’s... Read more »
AstraZeneca says it will establish centers for drug research and artificial intelligence development in China. The pharmaceutical giant has also set up a $1 billion fund to foster biotech innovation in that country.
Biogen is bolstering its strategy of selling biosimilars—lower-cost versions of biological drugs that are losing patent protection—with a $100 million deal for rights to two eye products. The drug maker is also expanding its biosimilar scope to include China.
Cambridge, MA-based... Read more »
The doors have opened at a GE Healthcare-supported open-access lab for startups at AstraZeneca’s former global center for oncology research and development at Alderley Park, the largest bioscience research campus in the UK.
Section 32, which invests in healthcare and life sciences companies with a technology component, has added a third managing partner.
The small venture capital firm was started in San Diego about two years ago by Bill Maris, who, during his... Read more »
Dauntless Pharmaceuticals formed in 2016, and its founders said the Sofinnova Ventures-backed firm planned to take a new approach to building biotechs.
An experimental Halozyme Therapeutics treatment for pancreatic cancer has failed a pivotal study, and the company is stopping further development of the drug and closing its oncology operations as part of a corporate restructuring.
Nearly one year after DNA sequencing machine maker Illumina announced plans to acquire smaller rival Pacific Biosciences, antitrust regulators in the UK say the merger could stifle competition in the region and reduce industry innovation.
The Competition and Markets Authority... Read more »
The FDA on Monday approved a Vertex Pharmaceuticals cystic fibrosis treatment that combines three drugs, a decision that comes three months after the company submitted its application and five months before the agency’s deadline to finish its review.
The Boston-based company... Read more »